1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Bosulif (Bosutinib) Film Coated Tablets

Trade Name: BOSULIF

Compound Number: WAY-173606; SKI-606

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Pfizer Inc

Pfizer Pharmaceuticals Group

235 East 42nd Street

New York, New York 10017

1-800-879-3477

Pfizer Ltd

Ramsgate Road

Sandwich, Kent

CT13 9NJ

United Kingdom

+00 44 (0)1304 616161

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Skin Sensitization: Category 1
Acute aquatic toxicity: Category 1
Chronic aquatic toxicity: Category 1

EU Classification:

EU Indication of danger: Irritant

Dangerous for the Environment

EU Risk Phrases:

R43 - May cause sensitization by skin contact.
R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Label Elements

Signal Word: Warning

Hazard Statements:

H317 - May cause an allergic skin reaction
H400 - Very toxic to aquatic life
H410 - Very toxic to aquatic life with long lasting effects
Precautionary Statements:
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P272 - Contaminated work clothing should not be allowed out of the workplace
P273 - Avoid release to the environment
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P302+P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P363 - Wash contaminated clothing before reuse
P391 - Collect spillage
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards
Australian Hazard Classification (NOHSC):
No data available
Hazardous Substance. Dangerous Goods.

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous</th>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bosutinib monohydrate</td>
<td>918639-08-4</td>
<td>Not Listed</td>
<td>Xi;R43 N;R50/53</td>
<td>Skin Sens. 1, H317; Aquatic Acute 1, Aquatic Chronic 1, H410</td>
<td>69</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opadry II yellow</td>
<td>Not Assigned</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>74811-65-7</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Povidone</td>
<td>9003-39-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Opadry II Red</td>
<td>Not Assigned</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium Stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose NF, monohydrate</td>
<td>64044-51-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Poloxamer 188</td>
<td>106392-12-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Cellulose microcrystalline</td>
<td>9004-34-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>
4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Bosutinib monohydrate
Pfizer OEL TWA-8 Hr: 40µg/m³, Sensitizer
Magnesium Stearate
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes: Wear safety glasses or goggles if eye contact is possible.
Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablet
Color: Red and Yellow
Odor: No data available.
Odor Threshold: No data available.
Molecular Formula: Mixture
Molecular Weight: Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
9. PHYSICAL AND CHEMICAL PROPERTIES

Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available
Partition Coefficient: (Method, pH, Endpoint, Value)
Cellulose microcrystalline
No data available
Croscarmellose sodium
No data available
Poloxamer 188
No data available
Povidone
No data available
Lactose NF, monohydrate
No data available
Magnesium Stearate
No data available
Opadry II Red
No data available
Opadry II yellow
No data available
Bosutinib monohydrate
Measured 8 Log P 3.34
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: May cause minimal eye irritation (based on animal data).
11. TOXICOLOGICAL INFORMATION

Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following exposure to this compound may include: nausea, diarrhea, vomiting, fatigue, loss of appetite (anorexia), and skin rash.

Acute Toxicity: (Species, Route, End Point, Dose)

Bosutinib monohydrate
Mouse Oral LD50 > 2000 mg/kg
Rat (M) Oral LD50 > 700mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Bosutinib monohydrate
Skin Corrosivity (In vitro, RHE) Human Negative
Eye Irritation (In vitro, BCOP) Negative
Skin Sensitization - LLNA Mouse Positive
Skin Irritation Rabbit Negative
Eye Irritation Rabbit Minimal

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Magnesium Stearate
13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Bosutinib monohydrate
1 Month(s) Rat Oral70 mg/kg/day NOAEL No effects at maximum dose
6 Month(s) Rat Oral 10 mg/kg/day NOAEL Gastrointestinal system
1 Month(s) Dog Oral 5 mg/kg/day NOAEL No effects at maximum dose
9 Month(s) Dog Oral 10 mg/kg/day NOAEL No effects at maximum dose

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Bosutinib monohydrate
Reproductive & Fertility Rat Oral3 mg/kg/day NOAEL Embryotoxicity, Maternal toxicity
Embryo / Fetal Development Rat Oral 10 mg/kg/day NOAEL No effects at maximum dose
Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOAEL Fetotoxicity, Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Bosutinib monohydrate
Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative
In Vivo Micronucleus Mouse Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Bosutinib monohydrate
2 Year(s) Rat Oral (M) 2.5 / (F) 1.5 mg/kg/day LOAEL Not carcinogenic, Gastrointestinal system

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
11. TOXICOLOGICAL INFORMATION

Povidone
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:
Environmental properties of the formulation have not been investigated. The following information is available for the individual ingredients.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Bosutinib monohydrate
_Pseudokirchneriella subcapitata_ (Green Alga) OECD ErC50 72 Hours 0.203 mg/L
_Pimephales promelas_ (Fathead Minnow) OECD NOEC 33 Days 0.066 mg/L
_Daphnia Magna_ (Water Flea) OECD NOEC 21 Days 0.145 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Bosutinib monohydrate
Activated sludge OECD EC50 > 1000 mg/L

Terrestrial Toxicity: (Species, Method, End Point, Duration, Result)

Bosutinib monohydrate
_Eisenia fetida_ (Earthworm) LC50 14 Days > 10 mg/kg
_Folsomia candida_ (Collembola) OECD NOEC 28 Days 250 mg/kg

Persistence and Degradability:
Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)
Bosutinib monohydrate
OECD Activated sludge Ultimate (CO2 Evolution) 0.2% After 28 Day(s)

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Bosutinib monohydrate
Measured 8 Log P 3.34

Mobility in Soil:
Sorption: (Method, Inoculum, Sorption Endpoint, Endpoint, Results)
Bosutinib monohydrate
OECD Activated sludge Adsorption Kd 3791
OECD Sediment Adsorption Kd 2262
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number: UN 3077
UN proper shipping name: Environmentally Hazardous Substance, Solid, n.o.s (Bosutinib)
Transport hazard class(es): 9
Packing group: III

5 kg/5L Exception: Effective January 1, 2015, UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not regulated as dangerous goods for transport by any mode:

* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.
* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
D2b toxic materials

Bosutinib monohydrate
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
EU EINECS/ELINCS List: Not Listed

Opadry II yellow
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>EU EINECS/ELINCS List</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Proposition 65</th>
<th>Australia (AICS):</th>
<th>REACH - Annex IV - Exemptions from the obligations of Register:</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Croscarmellose sodium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Povidone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opadry II Red</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Magnesium Stearate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Lactose NF, monohydrate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Poloxamer 188</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
<tr>
<td>Cellulose microcrystalline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction
Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

N - Dangerous for the environment
Xi - Irritant

R43 - May cause sensitization by skin contact.
R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 14 - Transport Information. Updated Section 2 - Hazard Identification.
Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 09-Mar-2015
Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet